Patents by Inventor Kiyoshi Osatomi

Kiyoshi Osatomi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-HIV monoclonal antibody
    Patent number: 6114143
    Abstract: A monoclonal antibody useful for clinical application which recognizes the conserved region of V3-PND region of glycoprotein antigen having a molecular weight of about 1.2.times.10.sup.5 daltons (gp120) on a coating membrane of human immunodeficiency virus (HIV) and which has an ability to neutralize a broad range of various HIV variants, or a fragment thereof, and the chimeric and humanized antibodies derived therefrom are provided. By using as an immunogen a plurality of peptides having PND-Tip region containing the highly conserved GPGR sequence within PND of HIV gp120, a monoclonal antibody having a neutralizing activity to many HIV variants can be prepared. By transplanting the gene fragment coding for the variable region of said monoclonal antibody or complementarity determining region (CDR) of said region to a human antibody gene, a chimeric antibody or a reshaped antibody having an anti-HIV neutralizing activity which are effective for clinical application can be obtained.
    Type: Grant
    Filed: September 11, 1995
    Date of Patent: September 5, 2000
    Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research Institute
    Inventors: Yasuyuki Eda, Hiroaki Maeda, Keiichi Makizumi, Kouichi Shiosaki, Kiyoshi Osatomi, Kazuhiko Kimachi, Hirofumi Higuchi, Sachio Tokiyoshi
  • Recombinant anti-HIV antibody and process for preparing the same
    Patent number: 5773247
    Abstract: The present invention relates to a gene fragment coding for a variable region of an antibody having a neutralizing activity against human immunodeficiency virus (HIV) and a process for preparing the same. A mouse-human chimeric antibody and a mouse-human reshaped antibody having a neutralizing activity against HIV can be prepared by obtaining a specific nucleotide sequence of a gene fragment coding for a variable region of H chain and L chain of an antibody having a neutralizing activity against HIV, and then artificially fusing DNAs synthesized based on these nucleotide sequences with a gene coding for a human immunoglobulin. The novel recombinant anti-HIV antibody of the present invention is useful for treatment and prevention of AIDS.
    Type: Grant
    Filed: July 14, 1995
    Date of Patent: June 30, 1998
    Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research Institute
    Inventors: Hiroaki Maeda, Kazuhiko Kimachi, Yasuyuki Eda, Kouichi Shiosaki, Kiyoshi Osatomi, Sachio Tokiyoshi
  • HIV monoclonal antibody specific for the HTLV-III.sub.mn gp120 envelope glycoprotein
    Patent number: 5712373
    Abstract: A murine monoclonal antibody which specifically binds to a glycoprotein antigen having a molecular weight of about 12.times.10.sup.4 daltons (gp120) present in the envelope of human T-lymphotropic virus III.sub.MN (HTLV-III.sub.MN) and capable of neutralizing the HTLV-III.sub.MN as determined by in vitro inhibition of syncytium formation but does not bind to other HTLV-III strains, or antigen-binding fragments, which is useful for prophylaxis, treatment and diagnosis of AIDS.
    Type: Grant
    Filed: June 2, 1994
    Date of Patent: January 27, 1998
    Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research Institute
    Inventors: Yasuyuki Eda, Kiyoshi Osatomi, Kouichi Shiosaki, Sachio Tokiyoshi, Shuzo Matsushita, Toshio Hattori, Kiyoshi Takatsuki